Still, only 8.5% of individuals discontinued the use of orlistat due to these side effects, and only two serious adverse events were reported as being associated with the medication
doi: 10.1074/jbc.M109.041376 26
More recently, on October 22, 2024, Novo Nordisk, the creator of the Ozempic (semaglutide) and Wegovy (semaglutide) injections, nominated its semaglutide glucagon-like peptide 1 (GLP-1) medications to be listed
Whats more, 60% of GLP-1 users said they were likely to treat themselves to higher-quality brand-name clothes as a reward for their weight loss success
Lipofirm is a 3-in-1 treatment that reduces fat, tightens skin, and activates muscle, targeting inch loss, toning, and skin laxity together